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Abstract
Background
The measurement of CMV specific cellular immunity in organ transplant recipients could
contribute additional acuity to serology based, CMV infection risk stratification, facilitating
optimisation of immunosuppression and anti-viral prophylaxis.
Methods
A pilot study of renal transplant recipient (RTR’s) responses in the T-SPOT.CMV ELISPOT
based assay. 108 RTR’s were recruited 3 months post-transplantation, immediately prior to
the cessation of stratified anti-viral prophylaxis, used in recipients from seropositive donors.
RTR’s were monitored for CMV viremia and disease. Cellular responses to peptides derived
from CMV IE1 and pp65 were measured, using the T-SPOT.CMV assay.
Results
At recruitment, no CMV specific cellular immunity was detected by T-SPOT.CMV in CMV
seronegative recipients (IE1 1spot / 2.5x105 PBMC’s; pp65 3 spots / 2.5x105 PBMC’s).
At recruitment, CMV sero-positive recipients who made a robust response to both IE1
(>25 spots / 2.5x105 PBMC’s) and pp65 (>50 spots / 2.5x105 PBMC’s), were less likely to
develop high level viremia than those who responded to one or neither antigen (0/28 vs
5/25; p<0.02).
Conclusions
In CMV seronegative RTR’s, CMV specific cellular immunity measured by T-SPOT.CMV
was not detected prior to cessation of anti-viral prophylaxis. This differs from recent reports
of CMV specific cellular immunity in a proportion of CMV seronegative RTR’s, associated
with protection from CMV infection. In seropositive RTR’s, a dual response to IE1 and pp65
at recruitment, was associated with protection from subsequent viremia. This suggests that
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assessing the diversity of response to CMV antigens, may enhance risk stratification in this
group.
Introduction
CMV disease is a major complication of organ transplantation, associated with increased mor-
bidity, mortality and allograft loss [1]. It is possible to stratify the risk of post-transplant CMV
disease using evidence of specific immunity in the recipient and latent infection in the donor.
In practice, these are both inferred from CMV specific humoral immunity, the donor and
recipient being referred to as seronegative (D- and R-) or seropositive (D+ and R+). The risk
of CMV disease is highest in D+R- recipients, and this group has therefore been the focus of
antiviral prophylaxis, in which there is clear evidence of benefit [2]. Although antiviral prophy-
laxis successfully suppresses early CMV disease, some recipients develop late disease after ces-
sation of prophylaxis; at a time when follow-up is less frequent and presentation may therefore
be delayed [1]. Evaluation of CMV disease risk beyond that achieved using donor and recipi-
ent CMV serostatus could further improve stratification of antiviral prophylaxis and immuno-
suppressive therapy. Since cellular immunity plays a pivotal role in controlling CMV infection,
it is hypothesized that its quantification could enhance current risk stratification algorithms.
For example, there is evidence that measures of serological and cellular immunity are discor-
dant in some individuals. This provides a possible explanation for relative disease resistance or
susceptibility in R- and R+ individuals respectively [3, 4].
The aim of this study was to pilot use of a new enzyme-linked immunospot (ELISPOT)
based assay (T- SPOT1.CMV assay; Oxford Immunotec Ltd, Oxfordshire, UK) in RTR’s
recruited 3 months post-transplantation, immediately prior to discontinuation of anti-viral
prophylaxis, which was used in serologically defined high risk sub-groups. This assay measures
the peripheral blood frequency of mononuclear cells producing γ-interferon to peptides
derived from the complete sequence of two CMV antigens (immediate early 1 (IE-1) and
phosphoprotein 65 (pp65)), with the potential to stimulate both class 1 and class 2 restricted
responses. We evaluated samples for CMV specific cellular responses to determine whether
detection of different CMV specific cellular responses predicts risk of infection or disease in
RTR’s.
Methods
The study was approved by the North-West (Lancaster) committee of the National Research
Ethics Service, UK. Participants were recruited following written informed consent. None of
the transplant donors were from a vulnerable population and all donors or next of kin pro-
vided written informed consent that was freely given. 115 adult recipients of solitary renal
transplants were screened from day 75 post renal transplantation and 108 patients recruited
for follow-up in a pilot, prospective, observational study of responses to CMV antigens in the
T-SPOT.CMV test. All recipients received center standard immunosuppression which con-
sisted of basiliximab induction followed by tacrolimus (target trough level 5–8 ng/ml, mea-
sured by liquid chromatography-tandem mass spectrometry), mycophenolate mofetil (2 g
daily initially), and prednisolone (20 mg daily, reducing to 5 mg maintenance by 3 months
after transplantation). CMV prophylaxis with 100 days of valganciclovir was used in D+R- and
the D+R+ groups.
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Baseline information was collected on the pre-transplant CMV serostatus of recipients and
their donors, donor and recipient age and sex, cause of renal failure, HLA mismatch, source of
transplant (living related, living unrelated, deceased donor following brain death, deceased
donor following cardiac death). Postoperative events of delayed graft function (requirement
for dialysis during the first postoperative week), biopsy-proven acute rejection and utilization
of antiviral prophylaxis were collected over the first post-transplant year. Patients were
excluded from recruitment, on the basis of anemia (Hemoglobin < 80g/L), if they had CMV
disease since transplantation or if they intended to change long-term follow-up to another
center (which was also the case for the 7 patients not included following screening due to a
subsequent change of intention). No patients screened had a history of CMV disease by this
timepoint.
Testing for CMV viremia was based on clinical indication with no real-time prospective
assessment of CMV viremia performed. CMV disease was diagnosed according to interna-
tional guidelines, based on one or more of the following in association with the finding of
CMV viremia: fever, new-onset severe malaise, leukopenia, thrombocytopenia, hepatitis (ala-
nine aminotransferase or aspartate aminotransferase levels greater than twice the upper limit
of normal) and tissue-invasive disease proven by histology [1].
Study assay
A T-SPOT.CMV test was undertaken on 5 occasions: 3, 4, 5, 6 and 12 months post-transplan-
tation, initially prior to cessation of anti-CMV prophylaxis if that had been used. The CMV
antigen specific response was reported as the frequency of spots per well containing 2.5 x 105
PBMC’s. T-SPOT.CMV test samples were shipped on the same day as collection to Oxford
Diagnostic Laboratories (Abingdon, UK), where the assay was performed within 32 hours of
blood draw as per the validated test protocol. Results were excluded from analyses if the nil
control was > 10 or if the PHA positive control failed to stimulate a response > 10 spots per
well. Laboratory personnel were blinded to the patients’ clinical information. Clinical person-
nel were blinded to the T-SPOT.CMV result. A spot count reported as> 10 well is defined as
positive by the manufacturer.
Other assays
A quantitative nucleic acid test (QNAT) was undertaken at 3, 4, 5, 6, 9 and 12 months post-
transplantation (Abbott RealTime CMV amplification kit and m2000 system (Ref 5N2390)).
The lower limit of detection was 20 copies/mL and the lower limit of quantification was 200
copies/mL of plasma.
CMV serostatus was determined 12 months post-transplantation in patients previously
determined to be seronegative prior to transplantation (Roche Elecsys CMV IgG assay (Ref
04784596) on a Roche modular E170). All other routine clinical assays were undertaken in the
Department of Pathology at Queen Elizabeth Hospital Birmingham. The results of all assays
were reported to the research team after study completion. High level viremia was defined as
>5000 copies/ml [5].
Statistical analysis
SPSS Statistics Version 21 (IBM, Armonk, USA) and Prism Versions 5 and 6 (GraphPad, La
Jolla, USA) were used. Data were assessed for normality using the D’Agostino & Pearson
omnibus normality test. Where assumptions of normality were not valid, data were analysed
nonparametrically and median with interquartile range reported. Correlations were assessed
with Pearson’s correlation, unpaired data with student’s t test (with Welch’s correction for
CMV interferon-γ release assay in renal transplant recipients
PLOS ONE | https://doi.org/10.1371/journal.pone.0193968 March 20, 2018 3 / 11
unequal variances if appropriate) or the Mann Whitney U test depending on normality
assumptions and paired data with paired t test or Wilcoxon matched-pairs signed rank test.
Comparisons between categorical variables were assessed with Fisher’s exact test. All statistical
analyses were two-tailed.
Results
Clinical outcomes and detection of viremia
The demographic and clinical variables of patients recruited to the study are summarized in
Table 1. Clinically indicated CMV QNAT was available to clinicians as part of standard care,
whilst on per protocol samples, CMV QNAT was undertaken at the end of the study.
Amongst 30 D-R- recipients, no cases of CMV disease or viremia were detected.
Amongst 25 D-R+ recipients, 1 patient developed CMV colitis. On per-protocol samples, 2
others were found to have high level viremia (>5000 copies/ml) on month 5 or 6 samples,
without CMV disease. 10 others had low level viremia detected on at least one occasion (maxi-
mum 742 copies/ml).
Amongst the 32 D+R+ recipients, 1 patient developed CMV colitis. On per-protocol sam-
ples, 2 others were found to have high level viremia on the month 5 or 6 samples, without
CMV disease. 12 others had low level viremia detected on at least one occasion (maximum 940
copies/ml).
Amongst 21 D+R- recipients, 3 were diagnosed with CMV colitis and 2 CMV syndrome
between month 5 and 6 post-transplantation. On per-protocol samples, one other recipient
was found to have high level viremia (61,865 copies/ml) at month 6. 3 others had low level vire-
mia detected on at least one occasion.
In the D-R+, D+R+, D+R- population, there were therefore 37/78 patients who were found
to be viremic on at least one occasion during 9 months of follow-up, despite the fact that
QNAT testing occurred no more often than monthly.
There were three patients who developed significant complications associated with other
herpes viruses: one patient varicella zoster, one patient varicella retinitis and one patient post-
transplant lymphoproliferative disorder.
T-SPOT.CMV test at recruitment
At recruitment (a median of 84 days post-transplantation), only one negative control con-
tained more than 1 spot (D-R+ recipient that failed negative control). The median positive
control response to PHA was 253 (IQR 105–348) spots per well (2.5 x 105 PBMC’s). The PHA
positive control was failed by one D+R+ and one D-R+ recipient. One recruitment sample was
unavailable for a D+R+ recipient.
The responses to IE1 and pp65 in the T-SPOT.CMV assay at recruitment, stratified by
donor and recipient CMV serostatus, are shown in Fig 1. At recruitment, the T-SPOT.CMV
assay was negative in all R- RTR’s (IE 1spot / well (2.5 x 105 PBMC’s); pp65 well 1spot /
well (2.5 x 105 PBMC’s).
In the 53 R+ RTR’s that passed control, the frequency of response to IE1 and pp65 were
widely distributed (IE1 median = 56, IQR 6–256 spots/well; pp65 median = 204, IQR 80–356
spots/well). There was no difference between those who received a kidney from D+ or D-
donors (p>0.4). In the T-SPOT.CMV assay at recruitment, the frequency of response to
both IE1 (abscissa) and pp65 (ordinate) in R+ RTR’s shown in Fig 2, correlate significantly
(p<10−3) but with a low coefficient of determination (R2 = 0.24).
In haematopoietic stem cell transplantation (HSCT) Nesher and colleagues recently pro-
posed thresholds for recipients’ T- SPOT.CMV responses of 50 spots per well for IE1 and
CMV interferon-γ release assay in renal transplant recipients
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100 spots per well for pp65 [6]. This was based upon protection from CMV infection in the
absence of graft vs. host disease. Applying these thresholds, 21/53 R+ RTR responded to both
antigens, a lower proportion response rate than defined in HSCT recipients by Nesher and
colleagues. We chose a lower threshold of 25 spots per well (2.5 x 105 PBMC’s) for IE1 and 50
spots per well (2.5 x 105 PBMC’s) for pp65, to dichotomize our population, which increased
Table 1. Demographic and clinical variables.
Recipient age / yrs (median (IQR) 49 (37–61)
Male recipients, n (%) 64 (59)
Recipient ethnicity, n
White 75
Indo-Asian 23
African-Caribbean 7
Other 3
Cause of renal failure, n (%)
Glomerular 22 (20)
Hereditary/cystic 25 (23)
Diabetes 7 (6)
Vascular 24 (22)
Interstitial 7 (6)
Other 23 (21)
Donor age (yr) 48.9
Transplant source, n (%)
Deceased donor
DBD 49 (45.4)
DCD 8 (7.4)
Live donor 51 (47.2)
Donor-recipient HLA mismatch
HLA-A 1.1
HLA-B 1.0
HLA-DR 0.7
Donor-recipient CMV serostatus
D—R— 30
D—R+ 25
D+R+ 32
D+R— 21
Day recruited post-transplantation (days) (interquartile range) 84 (79–91)
Immunosuppression on recruitment
(Basiliximab induction) (108)
Tacrolimus 106
MMF 98
Corticosteroid 108
Biopsy proven acute rejection 9
Patient survival at 9 months post-recruitment (1 year post transplantation), n (%) 108 (100)
eGFR (ml/min) (SD) 12 months post transplantation in surviving transplants 52 (30)
Graft survival at 9 months post recruitment (1 year post-transplant) n (%) 107 (99)
CMV disease at 12 months (5 D+R-, 1 D+R+, 1 D-R+) n 7
CMV QNAT > 5000 copies /mL at any time-point, n 12
https://doi.org/10.1371/journal.pone.0193968.t001
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the number defined as responding to both antigens to 28/53. Using these thresholds (shown
by dotted lines in Fig 2), CMV disease or viremia defined by a QNAT >5000 copies/ml, was
less frequent in R+ RTR’s in whom a response to both IE1 and pp65 antigens was detected
at recruitment, compared to those without a response to both IE1 and pp65 (0/28 vs 5/25;
p<0.02; Fisher’s exact test; cases of high level viremia shown as a triangle and all others by a
circle in Fig 2). This finding was not changed by reducing the QNAT threshold for viremia to
as low as 1000 copies/ml [5, 7].
T-SPOT.CMV and CMV specific IgG in D+R- RTR’s up to 12 months post-
transplantation
In the 9 D+R- RTR’s in whom viremia was detected during follow-up the T-SPOT.CMV assay
was always negative before the detection of viremia (S1 Table). The T-SPOT.CMV assay
became positive either at the time of detection of viremia or in the subsequent sample.
By 12 months post transplantation, of 5/21 D+R- recipients diagnosed with CMV disease, 3
made a robust response to both antigens as defined above (>25 spots per well for IE1 and>50
spots per well for pp65) and two did not (IE1 = 1 and 0 spot / well and pp65 = 9 and 47 spots/
well). These two ‘poor responders’ had persistent low-level viremia at 12 months post-trans-
plantation whereas the other 3 did not. Amongst the 4 D+R- RTR’s who were viremic without
symptoms, 3 made a robust response to both antigens 12-month post-transplantation (>25
spots per well for IE1 and>50 spots per well for pp65) but 1 responded only to pp65 (IE1 = 2
spot / well and pp65 = 81 spots/well). No viremia was detected by 12 months in these 4 asymp-
tomatic RTR’s.
Amongst the 9/21 D+R- RTR’s in whom CMV viremia was detected, all seroconverted
when retested 12 months post-transplantation (data unavailable in one). Of the remaining
Fig 1. T-SPOT.CMV responses in renal transplant recipients at recruitment. T-SPOT.CMV test undertaken in renal transplant recipients at the time of study
recruitment (3 months post-transplantation) prior to cessation of anti-CMV prophylaxis. The IE1 and pp65 specific response, reported as the frequency of spots per
well containing 2.5 x 105 PBMC’s, are shown. In D+R+ and in D-R+ RTR’s the frequency of response to pp65 derived peptides was significantly higher compared to
IE1 derived peptides (p<0.05). There was no significant difference in the frequency of response to pp65 and IE1 between D+ and D- individuals (p = 0.43 for pp65 and
p = 0.59 for IE1).
https://doi.org/10.1371/journal.pone.0193968.g001
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12 patients in whom no CMV was detected by QNAT, two seroconverted by 12-months.
These two had no T-SPOT.CMV response detected on any sample. There was no T-SPOT.
CMV response, viremia or humoral response detected in the other 10 patients on any
sample.
T-SPOT.CMV and CMV specific IgG at 12 months in D-R- transplant
recipients
Amongst 30 D-R- recipients there was no evidence of CMV infection, T-Spot.CMV response
or sero-conversion by 12 months post-transplantation.
Fig 2. T-SPOT.CMV responses to pp65 and IE1 in R+ renal transplant recipients at recruitment. T-SPOT.CMV
test undertaken 3 months post-transplantation in R+ renal transplant recipients. The pp65 and IE1 specific response,
reported as the frequency of spots per well containing 2.5 x 105 PBMC’s, are shown on the ordinate and abscissa
respectively. Responses to pp65 and IE1 were significantly correlated (R2 = 0.24, p<0.001). The 28 recipients who
made robust cellular responses to both pp65 and IE1 (defined as> 50 spots for pp65 and> 25 spots for IE1; limits
displayed as dotted line) were less likely to subsequently develop high level CMV viremia (>5000 copies/ml, with or
without evidence of CMV disease) compared to all others (0/28 vs 5/25; p<0.02; Fisher’s exact). RTR’s subsequently
developing high level CMV viremia are identified by a triangle and all others by a circle.
https://doi.org/10.1371/journal.pone.0193968.g002
CMV interferon-γ release assay in renal transplant recipients
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Discussion
This study pilots the T-SPOT.CMV interferon-γ release assay (IGRA) in renal transplantation,
as a potential adjunct to serologically based CMV disease risk stratification. Precise attribution
of risk could contribute to targeted anti-viral and immunosuppressive strategies to improve
outcomes.
In our study, CMV seronegative RTR’s recruited prior to cessation of antiviral prophylaxis,
did not respond to IE1 or pp65 derived peptides in the T-SPOT.CMV IGRA, and could not
therefore contribute to the evaluation of risk in this group. This differs from reports in which
evidence of CMV specific cellular immunity is found in a proportion of seronegative individu-
als. These reports include that by Lucia and colleagues using IE1 and pp65 derived peptides in
a γ-interferon ELISPOT [3], by Manuel and colleagues using IE1 and pp65 derived peptides
in cell culture supernatant interferon-γ assay (Quantiferon-CMV1) [4] and by Banas and col-
leagues using a γ-interferon ELISPOT to whole protein (T-Track-CMV1) [8]. In contrast,
Abate and colleagues have reported that cellular immune responses to pp65 were concordant
with CMV serostatus in renal transplant recipients and in healthy women [9, 10].
As in our study, Lucia and colleagues measured γ-interferon ELISPOT responses to a set
of overlapping 15mer peptides derived from full length pp65 and IE1. Subjects were tested
prior to transplantation. They found approximately 30% of R- recipients responded to these
antigens. The distribution of responses of R+ recipients in their assay (IE1 45±95, pp65
120 ± 181 (mean ± SD) spots per 3x105 PBMC’s) are not obviously different from those
observed with the T-SPOT.CMV IGRA, suggesting that these contradictory findings do not
reflect simple differences in sensitivity of the respective assays. There are differences in meth-
odology such as their use of frozen and thawed PBMC’s and in the assay of CMV serostatus,
although these seem unlikely to account for the observed differences. Specifically, inter-rater
agreement across modern commercial assays of CMV serology are high, albeit that their per-
formance may require re-evaluation, in light of Lucia’s finding CMV specific B lymphocytes
in R- recipients.
Perhaps the most significant difference is that the IGRA was performed post-transplanta-
tion in our study, when recipients were immunosuppressed. It is therefore possible that CMV
specific T cell reactivity in R- recipients, was reduced below the level of detection. Since in
Lucia’s study [3], R- IGRA responders did so with significantly lower frequency than R+ IGRA
responders, the R- response may be more sensitive to the effects of immunosuppression.
Future studies might therefore define conversion and reversion rates in patients assessed pre-
and post-transplantation.
The study by Manuel and colleagues [4] recruited patients at a similar time-point to ours.
If later time-points were also included, 25% of R- recipients were found to respond in the
Quantiferon-CMV1 IGRA and they were observed to have a lower incidence of CMV disease
over the first post-transplant year. However, this included a proportion of recipients who
developed an IGRA response following the cessation of prophylaxis, which might then include
patients who develop cellular immunity following transient asymptomatic viremia: a finding
in 4/21 D+R- recipients in our cohort, after prophylaxis was stopped.
A recent study by Banas and colleagues [8] demonstrates significant variation in attribution
of CMV specific cellular immunity according to methodological platform, above and beyond
the question of the temporal relationship of testing to transplantation, immunosuppression
and prophylaxis. Using 3 different assays defining CMV specific immunity in seronegative
dialysis patients they identified cellular responses in 21/57, but these were discordant in all but
one individual. The method and timing of assays determining CMV specific cellular immunity
for clinical purposes therefore remains a matter for further assessment.
CMV interferon-γ release assay in renal transplant recipients
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Our observation that two D+R- recipients seroconverted without evidence of a cellular
response or viremia may relate to infrequent QNAT testing. They could have been transiently
viremic without symptoms. On the other hand, in the 4 recipients in whom viremia was docu-
mented and who seroconverted, there was also a T-SPOT.CMV response.
In the R+ cohort the CMV disease event rate was low, possibly because prophylaxis was
used in the D+R+ group, a strategy instituted at our centre following analysis of an earlier
series [11]. In light of this low event rate, high-level CMV viremia was used as a surrogate out-
come measure, which was subsequently related to the initial T-SPOT.CMV result. Any thresh-
old for asymptomatic viremia is to an extent arbitrary; we based our definition of high-level
viremia on the influential analysis by Humar and colleagues [5], although this does relate to an
era before valganciclovir based CMV prophylaxis. Our data suggest that in R+ recipients, a
response to both IE1 and pp65 at 3 months post-transplantation is associated with relative pro-
tection from subsequent high-level viremia. This observation is also consistent with finding
that in D+R- recipients who developed CMV disease following the cessation of anti-viral pro-
phylaxis, clearance of viremia occurred only in those who responded to both antigens by 12
months post-transplantation, although the numbers are too small to make any definitive con-
clusion. An important caveat is that this is a pilot study and any such conclusion requires
validation using the same IGRA and definitions of response. This may be possible following
completion of the PROTECT study (NCT02382211).
In CMV infected individuals, responses to IE-1 and pp65 dominate the CD8+ T cell
response, although there is significant inter-individual variation. In R+ recipients, some
reports suggest that the correlation between CMV disease and IGRA responses to pp65 and
IE1, is insufficient provide any clinical utility [3, 9]. They did not however analyse the com-
bined response to both pp65 and IE1. Interestingly, in studies of solid organ transplantation it
is primarily the response to IE1 that has been linked to disease-protection [12, 13]. A poten-
tially related finding in our study is that the regression line between pp65 and IE1 T-SPOT.
CMV responses, has a highly positive intercept on the pp65 axis. That is, a high IE1 response
approximates to a high response to both pp65 and IE1.
Although the literature in clinical transplantation is dominated by these high frequency
CD8+ T cell responses to pp65 and IE1 [14], there is increasing evidence that responses to
other CMV antigens [15–17], by different arms of the immune system may be relevant to the
control of CMV infection and its pathogenesis [18–24]. Predicting disease protection from
responses to single antigens may therefore have intrinsic limitations [17]. The T-SPOT.CMV
IGRA uses these two antigens, represented by a full range of overlapping peptides, with poten-
tial to stimulate both class I and class II restricted T cell responses. It is therefore possible that
our preliminary observation of an apparent protection from high level viremia, in R+ recipients
who respond to both antigens, is the herald of a diverse CMV specific immune response.
In summary, in renal transplant recipients recruited 3 months post-transplantation, we
found no evidence of CMV specific cellular immunity using the T-SPOT.CMV IGRA in
those without humoral immunity in the Roche Elecsys CMV IgG assay. A dual response to
both pp65 and IE1 may identify R+ renal transplant recipients relatively protected from CMV
reactivation, a finding that warrants further investigation. Asymptomatic, transient, low level
viremia in D+R- recipients was associated with the subsequent acquisition of a T-SPOT.CMV
IGRA response and with seroconversion.
Supporting information
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